Weiling X. Xu

71 Xinmin Street
Changchun, 130012, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Extracellular Volume Fraction Imaging for Hepatic Fibrosis: CT and MRI Implementation and Evidence.

Extracellular Volume Fraction Imaging for Hepatic Fibrosis: CT and MRI Implementation and Evidence.

Journal: Academic radiology
Published: March 05, 2026

Clinical outcome of ≥2% circulating tumor cells in newly diagnosed multiple myeloma: insights from a multicenter study.

Clinical outcome of ≥2% circulating tumor cells in newly diagnosed multiple myeloma: insights from a multicenter study.

Journal: Annals of medicine
Published: April 30, 2025

Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study.

Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study.

Journal: Hematological oncology
Published: December 05, 2024

The impact of high-risk cytogenetic abnormalities in extramedullary multiple myeloma in the era of novel agents: insights from a multicenter study.

The impact of high-risk cytogenetic abnormalities in extramedullary multiple myeloma in the era of novel agents: insights from a multicenter study.

Journal: BMC cancer
Published: November 03, 2024

Dissecting the high-risk property of 1q gain/amplification in patients with newly diagnosed multiple myeloma.

Dissecting the high-risk property of 1q gain/amplification in patients with newly diagnosed multiple myeloma.

Journal: American journal of cancer research
Published: September 12, 2024

Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study.

Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study.

Journal: Journal of hematology & oncology
Published: May 23, 2024

Dynamics of minimal residual disease and its clinical implications in multiple myeloma: A retrospective real-life analysis.

Dynamics of minimal residual disease and its clinical implications in multiple myeloma: A retrospective real-life analysis.

Journal: Clinical medicine (London, England)
Published: March 25, 2024

More than 2% circulating plasma cells as a prognostic biomarker in a large cohort of patients with newly-diagnosed multiple myeloma.

More than 2% circulating plasma cells as a prognostic biomarker in a large cohort of patients with newly-diagnosed multiple myeloma.

Journal: Annals of hematology
Published: May 09, 2023

Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma.

Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma.

Journal: Annals of hematology
Published: December 29, 2022

Dynamic monitoring of minimal residual disease in newly-diagnosed multiple myeloma.

Dynamic monitoring of minimal residual disease in newly-diagnosed multiple myeloma.

Journal: American journal of hematology
Published: November 14, 2022

The R2-ISS in a Multicenter Cohort of Chinese Patients With Newly Diagnosed Multiple Myeloma.

The R2-ISS in a Multicenter Cohort of Chinese Patients With Newly Diagnosed Multiple Myeloma.

Journal: HemaSphere
Published: November 03, 2022

Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma.

Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma.

Journal: American journal of hematology
Published: August 01, 2022
Showing 1-12 of 23

Last Updated: 09/26/2026